IDL Diagnostics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDLDX.ST research report →
Companyidldiagnostics.com
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025.
- CEO
- Anders Hultman
- IPO
- 2025
- Employees
- 20
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $100.21M
- P/E
- 72.25
- P/S
- 1.84
- P/B
- 0.67
- EV/EBITDA
- 5.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.15%
- Op Margin
- 5.36%
- Net Margin
- 2.54%
- ROE
- 1.03%
- ROIC
- 1.80%
Growth & Income
- Revenue
- $53.11M · -7.54%
- Net Income
- $-12,151,000 · 71.38%
- EPS
- $-0.05 · 70.72%
- Op Income
- $-10,721,000
- FCF YoY
- -288.04%
Performance & Tape
- 52W High
- $0.60
- 52W Low
- $0.25
- 50D MA
- $0.34
- 200D MA
- $0.39
- Beta
- 1.08
- Avg Volume
- 174.13K
Get TickerSpark's AI analysis on IDLDX.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IDLDX.ST Coverage
We haven't published any research on IDLDX.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IDLDX.ST Report →